|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
To determine whether MDM2 plays a role in human cancer, we have cloned the human MDM2 gene.
|
1614537 |
1992 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest that over-expression of MDM2 is seen in a relatively small number of haematological malignancies, and is associated with poor prognosis.
|
7803295 |
1994 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The p53 and MDM2 genes are part of a physiological pathway frequently impaired in human cancer.
|
8378080 |
1993 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Since p53 inactivation by gene mutation has an established role in the pathogenesis of undifferentiated (anaplastic) thyroid carcinoma, we reasoned that abrogation of p53 function by nuclear MDM2 protein accumulation might participate in the pathogenesis of certain well-differentiated thyroid cancers such as papillary cancer.
|
8612724 |
1995 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
|
8695156 |
1996 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we report the observation of five alternatively spliced mdm2 gene transcripts in a range of human cancers and their absence in normal tissues.
|
8705862 |
1996 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2 is a wild-p53 inducible protein which may form a complex with p53, abrogating its function, as has been found in human sarcomas and other malignancies. p21WAF1/CIP1 is another protein inducible by wild-type p53, involved in inhibiting cell-cycle progression, through binding to cyclin/cyclin-dependent-kinase complexes.
|
8943816 |
1996 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The results suggest that the MDM2 and CDK4 regions may be either coamplified or amplified independently, and they illustrate how the map positions of genes and their functions may interact to determine the pattern of DNA amplification in human malignancies.
|
8946202 |
1996 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Amplification of the MDM2 gene and overexpression of its protein have been observed in some human malignancies, and these abnormalities have a role in tumorigenesis through inactivation of p53 function.
|
9155050 |
1997 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
It was recently reported that the expression of alternatively spliced variants of mdm2 correlated with malignancy in ovarian tumors and bladder carcinomas.
|
9485008 |
1998 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MDM2-overexpressing human cancer cell lines (n = 3) were found to be resistant to growth inhibition after infection by p53-expressing adenovirus (Ad-p53), as compared to low MDM2-expressing tumors (n = 3), in vitro.
|
9516979 |
1998 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggest that disorder of P2XM expression may play a crucial role in the genesis of benign and malignant tumours in soft tissues, and that one or more genetic factors other than p53 or mdm2 contribute significantly to aberrant P2XM expression.
|
10376970 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The overall objective of the present study was to investigate the functions of MDM2 oncogene in tumor growth and the potential value of MDM2 as a drug target for cancer therapy.
|
10493945 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, several reports have associated molecular abnormalities of p53 and mdm2 in TGTs with their malignancies.
|
10651023 |
2000 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Mdm2 in cancer cells with otherwise wild-type p53 is believed to be an alternative mechanism for p53 inactivation during carcinogenesis.
|
10674873 |
1999 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Whilst p53 protein staining increased with malignant progression and KAI1 mRNA expression decreased, there was no significant correlation between the two patterns (p=0.33, adjusted for group, p=0.18) or when only cancer samples were analysed (p=0.065, adjusted for group, p=0.26), even when taking into account overexpression of MDM-2 protein as a pathway for inactivation of p53.
|
10767717 |
2000 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, the MDM2-p53 interaction may be a target for cancer therapy.
|
10788589 |
2000 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Abrogation of the normal p53 pathway is the most common molecular alteration in human cancer. p53 Gene status can be potentially assessed through the expression of proteins known to be activated by the wild-type p53 (wt p53) system, such as mdm2 and p21Waf1/Cip1.
|
11037343 |
2000 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Therefore, these results suggest that p53 14/19 modified tumor suppressor gene may be a promising therapeutic agent for human cancers that express abnormally high levels of mdm2 oncogene product.
|
11059788 |
2000 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A MboII polymorphism in exon 11 of the human MDM2 gene occuring in normal blood donors and in soft tissue sarcoma patients: an indication for an increased cancer susceptibility?
|
11087894 |
2000 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Several short forms of alternatively spliced Murine double minute 2 (MDM2) transcripts have recently been shown to correlate with high-grade malignancy in a number of human tumors.
|
11107050 |
2000 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The demonstration that PI3-kinase/Akt signaling affects Mdm2 localization provides insight into how this pathway, which is inappropriately activated in many malignancies, affects the function of p53.
|
11504915 |
2001 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In contrast, mdm2 amplification and an increase in mdm2 protein expression were found to be associated with malignancy and dedifferentiation, whereas p53 protein expression was only slightly increased.
|
11518050 |
2001 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Disruptions of the p16-CDK4/cyclin D1-pRb pathway (RB pathway) and the p14ARF-MDM2-p53 pathway (p53 pathway) are important mechanisms in the development of human malignancies.
|
11567230 |
2001 |